A Clinical Trial to study how safe and effective the new drug Melflufen is, when given together with Dexamethasone, in Patients who have a type of blood cancer

Mise à jour : Il y a 4 ans
Référence : EUCTR2012-004315-31

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

Phase I (completed) The primary objective of the Phase I portion of the study is to determine the MTD of the combination of melflufen and dexamethasone in patients with relapsed and/or relapsed-refractory multiple myeloma. Phase IIa To evaluate the objective response rate (including minimal response [MR]) to the combination of melflufen and dexamethasone and melflufen as single agent at the MTD determined in Phase I.


Critère d'inclusion

  • Relapsed and/or Relapsed-Refractory Multiple Myeloma